Hope Through Innovation
At theravia, our commitment to transforming lives drives our cutting-edge Research and Development efforts. We prioritize the discovery and development of novel therapies specifically tailored to rare or neglected diseases, areas often overlooked by traditional pharmaceutical research.
Through state-of-the-art methodologies and strategic collaborations with world-renowned experts, we are at the forefront of bringing treatments to market that target the underlying causes of these complex conditions.
Our commitment
R&D
R&D activities are designed to meet the challenge of developing innovative drugs that contribute to improving people health. Although our main focus is on rare diseases, Theravia R&D addresses also neglected diseases for which treatments have yet to be established or significantly improved.
By combining our in-depth scientific expertise with a patient-centered approach, we do not simply develop medicines; our goal is to create potential cures and life-changing therapies. Committed to addressing significant unmet needs and improving patients’ lives, we have several active preclinical and clinical development programs currently ongoing, positioning Theravia as a beacon of hope for patients and a promising opportunity for forward-thinking investors.
Therapeutic Areas
Registration
Fertility
Asset : Ther07
Phase 3
Phase 2
Allergy
Asset : Ther08
Phase 1
Epidermolysis bullosa
Asset : A001
Preclinical
Proof of concept
Several other products will begin clinical phase shortly